



Expert panel for de-branding of some drugsPosted AtSify.comIn what could come as a blow to pharmaceutical
companies investing in brand building, the task force,
headed by Dr Pronab Sen, Principal Advisor, Planning
Commission, examining pricing of drugs, has recommended
that certain essential medicines not be allowed to have
distinct identities.This is part of a slew of measures
suggested to control prices of drugs which include dismantling
the Drugs Price Control Order (DPCO), 1995, fixing a
ceiling on the retail price of formulations, asking
doctors to prescribe only generic drugs and pre-negotiating
the price of patented products.
September 01, 2005
|